Stock Comparison

ABT vs JNJ

Abbott Laboratories vs Johnson & Johnson

The Verdict

ABT takes this one.

Winner

ABT

Abbott Laboratories

2.2

out of 10

Risk Trap

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Head-to-Head

$151.9B

Market Cap

N/A

24.2

P/E Ratio

N/A

13.9%

Profit Margin

N/A

12.9%

Return on Equity

N/A

0.2

Debt-to-Equity

N/A

Moderate

Overall Risk

Conservative

2.2

DVR Score

1.0

The Deep Dive

ABT2.2/10

Abbott Laboratories remains a highly stable, diversified global healthcare leader, demonstrating robust operational execution with Q1 2026 revenue and adjusted EPS beating estimates. The recent $20.6B Exact Sciences acquisition strengthens its cancer diagnostics portfolio, contributing to an expected $3B in incremental 2026 sales. While Abbott possesses strong competitive moats, solid financial he...

Full ABT Analysis

JNJ1.0/10

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Full JNJ Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.